Tyme Technologies, Inc. (NASDAQ:TYME) Major Shareholder Sells $22,400.00 in Stock


Share on StockTwits

Tyme Technologies, Inc. (NASDAQ:TYME) major shareholder Michael Demurjian sold 20,000 shares of Tyme Technologies stock in a transaction that occurred on Monday, December 28th. The shares were sold at an average price of $1.12, for a total value of $22,400.00. Following the sale, the insider now directly owns 24,998,546 shares in the company, valued at approximately $27,998,371.52. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Michael Demurjian also recently made the following trade(s):

  • On Monday, December 21st, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.15, for a total value of $23,000.00.
  • On Monday, December 14th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.19, for a total transaction of $23,800.00.
  • On Monday, December 7th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.07, for a total transaction of $21,400.00.
  • On Monday, November 30th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.08, for a total transaction of $21,600.00.
  • On Monday, November 23rd, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $0.93, for a total transaction of $18,600.00.
  • On Monday, November 2nd, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $0.86, for a total transaction of $17,200.00.
  • On Monday, October 19th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.03, for a total value of $20,600.00.
  • On Friday, October 16th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.02, for a total value of $20,400.00.
  • On Wednesday, October 7th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.00, for a total value of $20,000.00.
  • On Friday, October 2nd, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $0.97, for a total value of $19,400.00.

Shares of NASDAQ TYME opened at $1.22 on Friday. Tyme Technologies, Inc. has a 12-month low of $0.85 and a 12-month high of $2.04. The firm’s 50-day moving average price is $1.07 and its 200-day moving average price is $1.11. The stock has a market capitalization of $158.81 million, a price-to-earnings ratio of -5.55 and a beta of 0.84.

Tyme Technologies (NASDAQ:TYME) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.05) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. On average, equities analysts forecast that Tyme Technologies, Inc. will post -0.28 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC purchased a new position in Tyme Technologies during the second quarter worth $44,000. Goldman Sachs Group Inc. grew its holdings in Tyme Technologies by 98.6% during the 2nd quarter. Goldman Sachs Group Inc. now owns 101,467 shares of the company’s stock valued at $135,000 after purchasing an additional 50,384 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in Tyme Technologies in the 2nd quarter worth about $936,000. Nuveen Asset Management LLC lifted its stake in Tyme Technologies by 45.2% in the second quarter. Nuveen Asset Management LLC now owns 364,068 shares of the company’s stock worth $484,000 after purchasing an additional 113,327 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Tyme Technologies by 12.5% during the second quarter. Charles Schwab Investment Management Inc. now owns 162,357 shares of the company’s stock valued at $216,000 after buying an additional 17,994 shares during the period. 14.00% of the stock is currently owned by hedge funds and other institutional investors.

Separately, Zacks Investment Research cut Tyme Technologies from a “buy” rating to a “hold” rating in a report on Friday, December 25th.

Tyme Technologies Company Profile

Tyme Technologies, Inc, a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma.

Featured Story: What are the Benefits of Index Funds?

Insider Buying and Selling by Quarter for Tyme Technologies (NASDAQ:TYME)

Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.